Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:JAZZ

Jazz Pharmaceuticals Q3 2026 Earnings Date & Estimates

Jazz Pharmaceuticals logo
$218.42 -4.03 (-1.81%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$218.50 +0.09 (+0.04%)
As of 10/9/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jazz Pharmaceuticals is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Jazz Pharmaceuticals in Q3 2026

Jazz Pharmaceuticals is expected to post earnings of $6.69 per share on revenue of $1.20 billion. Jazz Pharmaceuticals last reported on August 3, 2026, posting $5.71 per share and missing the $6.18 consensus estimate. Jazz Pharmaceuticals has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$6.69
Expected Revenue
$1.20 billion

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$5.71 (Missed by -$0.47)
Last Quarter Revenue
$1.21 billion
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Jazz Pharmaceuticals Q3 2026 Earnings FAQ

Jazz Pharmaceuticals (NASDAQ:JAZZ) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes.

Jazz Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Jazz Pharmaceuticals to post earnings of $6.69 per share for Q3 2026.

The consensus revenue estimate for Jazz Pharmaceuticals is $1.20 billion for Q3 2026.

Jazz Pharmaceuticals Earnings Headlines

Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Target Cut by Royal Bank Of Canada
October 10 at 2:19 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104742
BofA Securities Adjusts Jazz Pharmaceuticals Price Target to $313 From $307, Maintains Buy Rating
October 9 at 8:44 PM  |  marketscreener.comM
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
 |  Stansberry Research (Ad)
Jazz Pharmaceuticals plc Announces Retirement of Samantha Pearce as Chief Commercial Officer by June 30, 2027
October 9 at 8:44 PM  |  marketscreener.comM
Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals'
October 9 at 8:44 PM  |  cnbc.comhttps://www.cnbc.com/2026/10/09/cramers-lightning-round-im-going-to-say-yes-to-jazz-pharmaceuticals.html
RBC Trims Price Target on Jazz Pharmaceuticals to $296 From $299, Keeps Outperform Rating
October 8 at 11:48 PM  |  marketscreener.comM
See More Jazz Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jazz Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jazz Pharmaceuticals and other key companies, straight to your email.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals (NASDAQ:JAZZ) is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.

Jazz’s neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults. The company also markets Epidiolex, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex in applicable markets.

In oncology and hematology, Jazz offers products including Rylaze for acute lymphoblastic leukemia and lymphoblastic lymphoma, Vyxeos for certain cases of acute myeloid leukemia, Zepzelca for metastatic small cell lung cancer in the United States, and Defitelio for hepatic veno-occlusive disease following hematopoietic stem-cell transplantation. Jazz expanded its neuroscience business through the acquisition of GW Pharmaceuticals in 2021. The company was co-founded by Bruce Cozadd, who has served as its chair and chief executive officer.

View Jazz Pharmaceuticals Profile
Earnings Tools